Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0027651 (
tumor
)
685,946
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ninety-six patients with colorectal cancer (stage B2-C) were randomized to the control arm or to receive adjuvant chemotherapy with folinic acid, FU and
MMC
. Ninety-three patients are evaluable. The median follow up is 12 months. The average time between surgery and the start of therapy is 28 days. Toxicity is evaluable in 36 of 41 treated patients. Four patients (10%) failed to complete the projected treatment due to toxicity. Toxicity observed in 208 courses of therapy was mostly gastrointestinal and hematological. No cases of treatment related death or cancer-associated hemolytic uremic syndrome (C-HUS) were reported. The average relative dose intensity (rDI) of the projected treatment was 82.6%. Our study is ongoing and further patients are required to achieve statistically significant results.
Med Oncol
Tumor
Pharmacother 1991
PMID:5-Fluorouracil (FU) with folinic acid (FA) and mitomycin C (MMC) in the adjuvant treatment of colorectal carcinoma. Part I. Evaluation of toxicity. 174 2
Mitomycin C
, an antineoplastic agent, was covalently attached to bovine serum albumin through a spacer of the glutaryl group. Two different synthetic methods were adopted; one was by the prior glutarylation of albumin followed by binding to mitomycin C, and the other was by the synthesis of glutarylated mitomycin C followed by binding to albumin. Physicochemical properties of the conjugates, such as Stokes radius, molecular weight, and helical content, were comparatively examined. The glutarylation of albumin resulted in an increase in Stokes radius of the protein due to the conformational change. The conjugates significantly stabilized mitomycin C and liberated it gradually under the physiological condition (t1/2 = 66-84 h). Both conjugates accumulated effectively in the
tumor
tissues. However, the distribution behavior of the conjugates depended on physicochemical properties such as molecular size. Treatment with the conjugates suppressed the tumor growth and increased the survival rate in the
tumor
-bearing mice.
...
PMID:Properties of mitomycin C-albumin conjugates in vitro and in vivo. 177 8
Drug sensitivities of 76 human
tumor
lines/nude mice to 9 anti-cancer drugs were tested. Human
tumor
lines include pancreas cancers, brain tumors, neuroblastomas and etc. Tested anti-cancer drugs include
MMC
, 5-FU, and etc. When clinically equivalent dose of anti-cancer drugs were administered, drug sensitivities of these carcinomas were well correlated with clinical one, although blood brain barrier must be considered when brain tumors were tested. Our drug sensitivity panel revealed that cancers originated from the same organ showed the same tendency of drug sensitivity. Therefore, our drug sensitivity panel is thought to be useful to know the anti-cancer spectrum of newly developed anti-cancer drugs. Our panel is also useful to study the chemotherapy of rare cancers, because clinical studies of rare cancers are difficult. Expression of P-glycoprotein is correlated with drug resistance when treated with CED, but is not correlated with those when treated with MTD (maximum tolerate dose). That is human
tumor
lines with P-glycoprotein detected by C219 monoclonal antibody showed resistance to ADR, VCR and VLB when treated by CED, but the relationship was not observed when treated with MTD.
...
PMID:[Drug sensitivity panel of human cancers transplanted in nude mice]. 185 16
A 28 year old man suffering from calcifying carcinoma of the stomach underwent a gastrectomy which was histologically classified as being a noncurative resection. As postoperative adjuvant chemotherapy, he received 116 mg of
Mitomycin C
and 454.8 g of Tegafur as well as 5690 g of ascorbic acid. He showed carcinoma cells histologically at both oral and anal edges of the resected specimen, and peritoneal metastases of
tumor
cells were also observed, but he nevertheless kept a performance status of 1 until 5 years after surgery. The patient finally died of cachexia 5 years and 6 months after his operation. Among 42 patients with calcifying carcinoma of the stomach reported in the foreign literature and 19 patients reported in Japanese, those patients for whom the postoperative survival time was clearly indicated did not necessarily survive longer than those patients without calcification.
...
PMID:A case of calcifying carcinoma of the stomach with long-term postoperative survival. 185 37
There are few reports about the methods, amounts, and kinds of dosage about intermittent intra-arterial chemotherapy of liver metastases from primal pathological type's squamous cell carcinoma. Because they are less than liver metastases from adenocarcinoma of colon or stomach. Although it is important of other factors about the operative method of primary focus and metastases of the other parts, it is possible that those cases obtained the good prognosis and protected liver failure, if those liver metastases could be controlled well. In our department from January 1987 to December 1989, 9 cases of inoperative liver metastases of squamous cell carcinoma (esophagus: 4 cases, larynx: 3 cases and cervix of uterus 2 cases) were treated of intra-arterial infusion chemotherapy of FAM (5Fu 500 mg/week, ADM 30 mg/4 weeks and
MMC
4 mg/2 weeks) and CDDP methods (only CDDP 10 mg/week). Cases of esophagus carcinoma were treated with FAM method. On the CT-scan one of the cases showed the reduction rate of more than 50% and was a Progressive Response (PC), and the SCC
tumor
marker decreased in 2 cases. However, 2 other cases died of liver failure. Cases of larynx were treated with FAM and CDDP methods. However, on the CT-scan all of the cases showed No Change (NC) nor decrease in SCC. But thinking of prognosis FAM was better than CDDP. Cases of cervix of uterus were treated with the FAM and CDDP methods. FAM was not different than the CDDP in the prognosis and effect.
...
PMID:[Study of intermittent intra-arterial infusion chemotherapy in liver metastases from squamous cell carcinoma]. 188 84
The radiosensitizing and cytotoxic properties of
Mitomycin C
(
MMC
) was investigated in vivo using regrowth delay and
tumor
control assays.
MMC
significantly enhanced the radiation-induced growth delay when administered 15 min before irradiation; the slope of the dose response curve significantly increased and corresponded to a Dose Modifying Factor (DMF) of 1.9 (1.5-2.3; p less than 0.001). When
MMC
was given 4 hr after irradiation, the additional regrowth delay resulted in a parallel shift of the dose response curve, and
MMC
was not significantly dose modifying (DMF 1.3 (0.9-1.3); p less than 0.05). From isobologram analysis it was found that the preirradiation
MMC
schedule resulted in supra-additive responses, whereas
MMC
given after irradiation had an additive effect. The enhancement of radiation-induced
tumor
control was similarly found to peak when
MMC
was given 6 hr to 15 min prior to irradiation. At these intervals, the observed TCD50 for the combined treatments relative to radiation alone corresponded to Enhancement Ratios of 1.27 and 1.29, respectively (p less than 0.001). Longer intervals between the modalities reduced the enhancement, but the combined treatments were still significantly better than radiation alone (ER 1.12, 1.16 and 1.17; p less than 0.001). The significant enhancement of
tumor
control correlated with a substantial drug-induced cytotoxic effect toward hypoxic
tumor
cells, as determined by clamped TCD50 experiments. A single dose of
MMC
(3 mg/kg) was found to kill up to 97% of all hypoxic
tumor
cells.
...
PMID:Radiosensitizing and cytotoxic properties of mitomycin C in a C3H mouse mammary carcinoma in vivo. 189 13
Of our 276 patients with superficial bladder carcinoma, 242 were male, and 36 of these had recurrence in prostatic urethra, 26 with macroscopic tumors, and 10 with tumors in situ (TIS). These recurrences represent an incidence of 13.3%, with an average follow-up of 34.3 months. When the urethral
tumor
was limited to the mucosa, we chose conservative therapy, and the patients entered a random program with
Mitomycin
or Adriamycin administered endovesically. With this program, we could control the disease in 59.3% of the patients. However, 22.2% of them had recurrence with prostatic stromal infiltration, so that we performed a more exhaustive exploration of the prostate, taking biopsies not only at the 5 and 7 o'clock positions, but also making a wider resection in order to find the incipient infiltration of the prostatic stroma, and trying to avoid a possible understaging. When the urethral
tumor
had infiltrated the prostatic stroma, we performed cystoprostatourethrectomy, getting a survival rate free of disease of 40%. An association with vesical TIS was detected in 61.1% of these patients, with terminal ureteral
tumor
in 8.3% and with the anterior urethra in 11.1%, showing the diffuse pattern of the disease. We conclude that when recurrence of prostatic urethra is present, it is necessary to monitor the whole urothelium during follow-up.
...
PMID:Recurrence of superficial bladder tumors in prostatic urethra. 190 17
During an intra-arterial chemotherapy of patients with liver metastases the plasma concentration-time curves of
Mitomycin C
(1) after occlusion of the common hepatic artery by the vasoconstricting agent Glycylpressin (2) were investigated. Vasoconstriction by 2 leads to significantly (p less than 0.01) lower blood levels of 1 in contrast to bolus injection of 1 without 2 under identical dosage regimens. This reduction of systemic availability of about 50% leads to a corresponding higher availability for the
tumor
region.
...
PMID:[The effect of the vasoconstrictor glycylpressin on the bioavailability of mitomycin C]. 190 14
Anti-
tumor
effects of etoposide (VP-16), vincristine and mitomycin C were evaluated with four human neuroblastoma xenograft, according to Battelle Columbus Laboratories protocol. Etoposide is one of the agents which has been reported to be effective against advanced neuroblastoma clinically, if combined with other agents. While vincristine was effective against 1 out 4 neuroblastoma xenografts, TS-N-2, with 58.1% maximum inhibition rate, etoposide was assessed ineffective as a single agent in all of the 3 xenografts used. Since etoposide had no effect on the weight gain in nude mice in this xenograft experiment, the dose of etoposide was increased two-fold against 2 xenografts, but found ineffective also in the increased dose.
Mitomycin C
, which has not been used in childhood malignant tumors, was effective against 2 out of 4 xenografts, TNB-9 and SK-N-AS, with 72.0% and 78.4% maximum inhibition rates, respectively.
...
PMID:[In vivo assessment on the therapeutic effects of etoposide, vincristine and mitomycin C against human neuroblastoma]. 190 21
A 61-year-old male diagnosed as Borrmann type 3 advanced gastric cancer was operated, but could not be resected because of the invasion to the pancreas and the lymph nodes metastases. So, local administration of OK-432 20 KE, intra-abdominal administration of CDDP 50 mg, and long-term intermittent intravenous administration of
MMC
a total amount of 1480 mg, and oral administration of UFT were performed. As the result of this therapy, the
tumor
was reduced in size. Three years and seven months after the operation, he feels well. Because of this combined therapy, his renal function was made worse.
...
PMID:[A case of inoperable advanced gastric cancer with effective treatment by local administration of OK-432, intra-abdominal administration of CDDP, and long-term high-dose mitomycin C, and UFT]. 190 22
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>